{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+saline&page=38",
    "query": {
      "intervention": "Injectable saline",
      "page": 38
    },
    "page_size": 10
  },
  "pagination": {
    "page": 38,
    "page_size": 10,
    "total_count": 2100,
    "total_pages": 210,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+saline&page=39&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+saline&page=37&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T14:24:10.998Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05515874",
      "title": "Predicting Stroke Risk in ICAD With Novel MRI",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Intracranial Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "Feraheme",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2020-09-01",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-28T14:24:10.998Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05515874"
    },
    {
      "nct_id": "NCT03172910",
      "title": "Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ciraparantag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 69,
      "start_date": "2017-05-08",
      "completion_date": "2019-11-12",
      "has_results": true,
      "last_update_posted_date": "2025-09-02",
      "last_synced_at": "2026-10-28T14:24:10.998Z",
      "location_count": 1,
      "location_summary": "Secaucus, New Jersey",
      "locations": [
        {
          "city": "Secaucus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03172910"
    },
    {
      "nct_id": "NCT05500417",
      "title": "Safety and Immunogenicity of CJCV2 With and Without ALFQ",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Campylobacter Infection"
      ],
      "interventions": [
        {
          "name": "ALFQ",
          "type": "DRUG"
        },
        {
          "name": "CJCV2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 59,
      "start_date": "2022-09-13",
      "completion_date": "2025-01-02",
      "has_results": true,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-10-28T14:24:10.998Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05500417"
    },
    {
      "nct_id": "NCT05547906",
      "title": "Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "ASCA101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MetaFines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2021-11-08",
      "completion_date": "2024-02-29",
      "has_results": false,
      "last_update_posted_date": "2024-03-13",
      "last_synced_at": "2026-10-28T14:24:10.998Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05547906"
    },
    {
      "nct_id": "NCT07871825",
      "title": "Study of G-CSF for DOR in Patients Undergoing IVF",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diminished Ovarian Reserve",
        "IVF",
        "G-CSF",
        "Granulocyte Colony Stimulating Factor"
      ],
      "interventions": [
        {
          "name": "Neupogen 300 μg subcutaneous injection",
          "type": "DRUG"
        },
        {
          "name": "Subcutaneous injections of a saline solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Center for Human Reproduction",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "44 Years",
        "sex": "FEMALE",
        "summary": "35 Years to 44 Years · Female only"
      },
      "enrollment_count": 140,
      "start_date": "2026-02-25",
      "completion_date": "2031-02-25",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-28T14:24:10.998Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07871825"
    },
    {
      "nct_id": "NCT02002806",
      "title": "Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pancreas Cancer",
        "Biliary Tract Cancer"
      ],
      "interventions": [
        {
          "name": "Alcohol Injection",
          "type": "OTHER"
        },
        {
          "name": "Placebo Injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 150,
      "start_date": "2012-01",
      "completion_date": "2019-06",
      "has_results": false,
      "last_update_posted_date": "2019-08-16",
      "last_synced_at": "2026-10-28T14:24:10.998Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02002806"
    },
    {
      "nct_id": "NCT05696184",
      "title": "Mechanisms Preventing Pharyngeal Reflux",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "GERD"
      ],
      "interventions": [
        {
          "name": "Concurrent manometry/impedance/pH with video pharyngo-laryngoscopy",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Slow and rapid intra-esophageal infusion",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 300,
      "start_date": "2013-11-01",
      "completion_date": "2026-10-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-10-28T14:24:10.998Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05696184"
    },
    {
      "nct_id": "NCT03346252",
      "title": "The Effect of Botulinum Toxin A on Headache Attributed to TMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Secondary Headache Disorder"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxin type A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "State University of New York at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 74 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2017-05-08",
      "completion_date": "2021-03-15",
      "has_results": false,
      "last_update_posted_date": "2022-10-04",
      "last_synced_at": "2026-10-28T14:24:10.998Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03346252"
    },
    {
      "nct_id": "NCT00439140",
      "title": "Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "botulinum toxin Type A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline (Placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 41,
      "start_date": "2007-06",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2014-01-24",
      "last_synced_at": "2026-10-28T14:24:10.998Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00439140"
    },
    {
      "nct_id": "NCT02002884",
      "title": "Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cerebral Palsy",
        "Spasticity"
      ],
      "interventions": [
        {
          "name": "IncobotulinumtoxinA (8 Units per kg body weight)",
          "type": "DRUG"
        },
        {
          "name": "IncobotulinumtoxinA (6 Units per kg body weight)",
          "type": "DRUG"
        },
        {
          "name": "IncobotulinumtoxinA (2 Units per kg body weight)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merz Pharmaceuticals GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 351,
      "start_date": "2014-03-28",
      "completion_date": "2018-08-28",
      "has_results": true,
      "last_update_posted_date": "2021-08-05",
      "last_synced_at": "2026-10-28T14:24:10.998Z",
      "location_count": 6,
      "location_summary": "Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more",
      "locations": [
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        },
        {
          "city": "Loxahatchee Groves",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02002884"
    }
  ]
}